Guilherme Nader-Marta

14PUBLICATIONS
75CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGlycoconjugatesTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

|Jun 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.

|Jun 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Karen Van Baelen, Ha-Linh Nguyen, François Richard

|Oct 07, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek

|Oct 19, 2023
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors.

Diogo Martins-Branco, Guilherme Nader-Marta, Andrea Gombos

|Jul 12, 2023
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.

Guilherme Nader-Marta, Chiara Molinelli, Véronique Debien

Pageof 3

Frequent Collaborators

4 joint publications

Evandro de Azambuja

3 joint publications

Diogo Martins-Branco

3 joint publications

Elisa Agostinetto

2 joint publications

Veronique Debien